Puma Biotechnology, Inc.
PBYI
$6.07
$0.172.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.45M | 54.48M | 52.44M | 46.01M | 59.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.45M | 54.48M | 52.44M | 46.01M | 59.08M |
| Cost of Revenue | 23.13M | 12.17M | 12.30M | 10.56M | 13.92M |
| Gross Profit | 52.33M | 42.30M | 40.14M | 35.45M | 45.16M |
| SG&A Expenses | 18.38M | 16.82M | 18.05M | 17.60M | 16.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.35M | 44.90M | 45.80M | 42.02M | 45.71M |
| Operating Income | 17.11M | 9.57M | 6.64M | 3.98M | 13.37M |
| Income Before Tax | 17.11M | 9.24M | 6.17M | 3.27M | 12.24M |
| Income Tax Expenses | 3.67M | 399.00K | 310.00K | 293.00K | -7.07M |
| Earnings from Continuing Operations | 13.44M | 8.84M | 5.86M | 2.97M | 19.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.44M | 8.84M | 5.86M | 2.97M | 19.31M |
| EBIT | 17.11M | 9.57M | 6.64M | 3.98M | 13.37M |
| EBITDA | 18.96M | 12.30M | 9.40M | 6.78M | 14.81M |
| EPS Basic | 0.27 | 0.18 | 0.12 | 0.06 | 0.39 |
| Normalized Basic EPS | 0.21 | 0.11 | 0.08 | 0.04 | 0.16 |
| EPS Diluted | 0.26 | 0.17 | 0.12 | 0.06 | 0.39 |
| Normalized Diluted EPS | 0.21 | 0.11 | 0.08 | 0.04 | 0.15 |
| Average Basic Shares Outstanding | 50.34M | 50.34M | 49.70M | 49.60M | 49.10M |
| Average Diluted Shares Outstanding | 51.52M | 50.93M | 50.14M | 49.91M | 49.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |